Research programme: synthetic macrocycles - Ensemble Therapeutics/Novartis
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Ensemble Therapeutics; Novartis
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA
- 06 Aug 2013 Early research in Undefined indication in USA (unspecified route)